Mariangela Figini
Laboratory of Molecular Biology
CancerAntigenMolecular biologyAntibodyReceptorChemistryImmunologyIn vivoImmunotherapyProstate cancerFolate receptorOvarian cancerOvarian carcinomaChimeric antigen receptorCancer researchMonoclonal antibodyMedicineBiologyImmune systemCancer cell
76Publications
26H-index
2,263Citations
Publications 79
Newest
#2Arianna MicaliH-Index: 1
Last. Mariangela FiginiH-Index: 26
view all 11 authors...
Since the beginning of the COVID-19 outbreak, Cancer Centers adopted specific procedures both to protect patients and to monitor the possible spread of SARS-CoV-2 among healthcare personnel (HCP). In April 2020 at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, one of the three oncologic hubs in Lombardy where the Health Regional Authorities referred all the cancer patients of the region, we implemented a prospective longitudinal study aimed at monitoring the serological response to SARS...
Source
BACKGROUND Choline kinase-α (ChoKα/CHKA) overexpression and hyper-activation sustain altered choline metabolism conferring the cholinic phenotype to epithelial ovarian cancer (OC), the most lethal gynecological tumor. We previously proved that CHKA down-modulation reduced OC cell aggressiveness and increased sensitivity to in vitro chemotherapeutics' treatment also affecting intracellular content of one-carbon metabolites. In tumor types other than ovary, methionine decrease was shown to increas...
Source
#1Mano Nakamura (Guy's Hospital)H-Index: 1
#1Mano Nakamura ('KCL': King's College London)H-Index: 6
Last. Sophia N. Karagiannis (Guy's Hospital)H-Index: 31
view all 20 authors...
1 CitationsSource
#1Silvia MartiniH-Index: 3
#2Mariangela FiginiH-Index: 26
Last. Alessandro SattaH-Index: 4
view all 12 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells against tumors, has shown promising results. In particular, a BsAb that uses TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) as a target was constructed and demonstrated good results in redirec...
2 CitationsSource
#1A.I. Fraguas-Sánchez (Complutense University of Madrid)H-Index: 7
#2A. Fernández-Carballido (Complutense University of Madrid)H-Index: 14
Last. Ana Isabel Torres-Suárez (Complutense University of Madrid)H-Index: 13
view all 9 authors...
Abstract In this work, we evaluated, for the first time, the antitumor effect of cannabidiol (CBD) as monotherapy and in combination with conventional chemotherapeutics in ovarian cancer and developed PLGA-microparticles as CBD carriers to optimize its anticancer activity. Spherical microparticles, with a mean particle size around 25 µm and high entrapment efficiency were obtained. Microparticles elaborated with a CBD:polymer ratio of 10:100 were selected due to the most suitable release profile...
Source
The clinical translation of theranostic 177Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, challenges still remain, particularly regarding their pharmacokinetic and dosimetric properties. We developed a potential PSMA-immunotheranostic agent by conjugation of a single-chain variable fragment of the IgGD2B antibody (scFvD2B) to DOTA, to obtain a 177Lu...
Source
#1Ricarda M. Hoffmann ('KCL': King's College London)H-Index: 5
#2Silvia Mele (Guy's Hospital)H-Index: 12
Last. Silvia Crescioli ('KCL': King's College London)H-Index: 13
view all 17 authors...
Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use. However, selection of an optimum target and payload combination, to achieve maximal therapeutic efficacy without excessive toxicity, presents a significant challenge. We have developed a platform to facilitate rapid and cost-effective screening of antib...
2 CitationsSource
Background Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease and detection of metastatic lesions. Prostate-specific membrane antigen (PSMA) expression, directly related to androgen-independence, metastasis and progression, renders this tumour associate ant...
5 CitationsSource
Folate receptors and transporters and one-carbon metabolism continue to be important areas of study given their essential roles in an assortment of diseases and as targets for treatment of cancer and inflammation. Reflecting this, every 2 years, the Folate Receptor Society organizes an international meeting, alternating between North America and Europe, where basic and translational scientists, clinical oncologists and rheumatologists from both academia and industry convene in an informal settin...
17 CitationsSource
#1Alessandro SattaH-Index: 4
#2Giulia GraziaH-Index: 9
Last. Mariangela FiginiH-Index: 26
view all 11 authors...
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymphocytes towards cancer cells by bispecific antibodies (bsAbs) that engage the CD3 complex and a tumor-associated antigen (TAA). The TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) is an attractive immunotherapy target, frequently expresse...
4 CitationsSource
12345678
Close Researchers